Zobrazeno 1 - 10
of 1 198
pro vyhledávání: '"SUBCUTANEOUS IMMUNOGLOBULIN"'
Publikováno v:
BMC Immunology, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Background Here, the perspective of patients with primary and secondary immunodeficiency receiving subcutaneous immunoglobulin (SCIg) via introductory smaller size pre-filled syringes (PFS) or vials were compared. Methods An online survey wa
Externí odkaz:
https://doaj.org/article/be221d307fa24e11990c35ed988a499a
Autor:
Archan Sil, Suprit Basu, Vibhu Joshi, Rakesh Kumar Pilania, Sangeetha Siniah, Deepti Suri, Amit Rawat, Surjit Singh
Publikováno v:
Frontiers in Pediatrics, Vol 12 (2024)
Immunoglobulins (Ig) were used as a therapeutic modality for the first time in a patient with X-linked agammaglobulinemia in 1952 by Colonel Ogden Bruton, decades before the molecular mechanisms causing the disease were unraveled. In many autoimmune
Externí odkaz:
https://doaj.org/article/8e753cbeee0e490cbc293af466f393a8
Autor:
Taylor Pindi Sala, MD, PhD, Daniel Matondo Masisa, MD, MPH, Jean Charles Crave, MD, PhD, Chafke Belmokhtar, PhD, Guillaume LeNy, PhamD, Hippolyte Situakibanza, MD, PhD, Martin Duracinsky, MD, PhD, Patrick Cherin, MD, PhD, Olivier Chassany, MD, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 1, Pp 100173- (2024)
Background: Long-term therapeutic adherence remains an essential challenge for better management of chronic diseases. It is estimated at 50% in developed countries. Objective: The study aimed to evaluate, under real conditions, the influence of satis
Externí odkaz:
https://doaj.org/article/97cd8f91c8f14fe3b968412a360718d7
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 18, Iss 1, Pp 1-11 (2022)
Abstract Immunoglobulin replacement therapy is the standard-of-care treatment for patients with primary immunodeficiency diseases who have impaired antibody production and function. Clinicians and patients may consider intravenous immunoglobulin (IVI
Externí odkaz:
https://doaj.org/article/605cf15107bc439b96f3405df436cf79
Autor:
Andrea Visentin, Maria Chiara Molinari, Stefano Pravato, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavaretta, Valeria Ruocco, Silvia Imbergamo, Francesco Piazza, Giulia Proietti, Francesca Romana Mauro, Livio Trentin
Publikováno v:
Current Oncology, Vol 30, Iss 1, Pp 274-283 (2022)
Secondary antibody deficiency (SAD) is a common complication in chronic lymphocytic leukemia (CLL) which favors the development of life-threatening infections. Subcutaneous immunoglobulins (IG) (SCIG) have been proven to be as effective as intravenou
Externí odkaz:
https://doaj.org/article/c03cd60533f84201be41e7bc39896880
Autor:
Rajiv Mallick, Geneviève Solomon, Paul Bassett, Xiang Zhang, Palak Patel, Oleksandra Lepeshkina
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 18, Iss 1, Pp 1-20 (2022)
Abstract Background Understanding the impact of different immunoglobulin (Ig) infusion methods (intravenous [IVIg] and subcutaneous [SCIg]) upon treatment experience can potentially facilitate optimization of patient outcomes. Here, the perspective o
Externí odkaz:
https://doaj.org/article/8e278443240d4b07b9566a497be7d035
Publikováno v:
Hematology Reports, Vol 14, Iss 4, Pp 342-348 (2022)
Objective: Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig® treatment offered a tolerable and safe alternative
Externí odkaz:
https://doaj.org/article/e8102888c9494afbb2b259877a3c9100
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.